ExonHit Announces Final Terms for RedPath Acquisition | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics today disclosed the final terms of its proposed acquisition of RedPath.

Under the terms, which are up for a vote by shareholders, ExonHit will pay $12.5 million in cash and $10 million in stock. ExonHIt will issue 2,834,412 new shares of its stock, which represents 7.95 percent of the 35,656,294 ordinary shares that will be outstanding after the close of the purchase.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.